EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease

Xin Li, Xuerong Liu, Xinran Song, Yinglian Zhou, Dan Yang, Yifei Wang, Senlin Mao, Xinming Rang, Xiangxiang Hong, Xu Wang, Hui Yue, Duo Wang und 1 weitere

BioMed Research International · 2026

DOI: 10.1155/bmri/8975137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2026. Verfasst von Xin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Computational Biology. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The deposition of amyloid‐ β (A β ) plaque is widely recognized as one of the core pathological events of Alzheimer′s disease (AD). This study focused on uncovering potential diagnostic biomarkers and small‐molecule candidates potentially modulating A β ‐associated pathways in AD. Weighted gene coexpression network analysis (WGCNA) and machine learning identified the hub gene. Single‐nucleus RNA sequencing (snRNA‐seq) identified high‐expression cell clusters. We identified potential A β ‐binding small‐molecule candidates and calculated their binding affinities using molecular docking techniques. Based on molecular docking, we further evaluated the binding stability and conformational dynamics of the protein–ligand complex through molecular dynamics (MD) simulations. NFKBIA was identified as a hub diagnostic gene. Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA. These findings clarify the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersComputational BiologyHumansMolecular Docking SimulationCurcuminMolecular Dynamics SimulationResveratrolApigeninGene Regulatory NetworksProtein Binding

Stichwörter der Autor:innen

Alzheimer′s diseaseamyloid-betarisk markerssmall molecule drugs

Substanzen

Amyloid beta-PeptidesBiomarkersCurcuminResveratrolApigenin

Autor:innen und Institutionen

  • Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.

ORCID-Profile: Xuemei Zhang

Förderung

  • Heilongjiang Provincial Natural Science Foundation

Zitieren

APA

Li, X., Liu, X., Song, X., Zhou, Y., Yang, D., Wang, Y., Mao, S., Rang, X., Hong, X., Wang, X., Yue, H., Wang, D., & Zhang, X. (2026). Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease. BioMed Research International. https://doi.org/10.1155/bmri/8975137

Vancouver

Li X, Liu X, Song X, Zhou Y, Yang D, Wang Y, et al. Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease. BioMed Research International. 2026. doi:10.1155/bmri/8975137

BibTeX
@article{Li2026,
  author = {Li, Xin and Liu, Xuerong and Song, Xinran and Zhou, Yinglian and Yang, Dan and Wang, Yifei and Mao, Senlin and Rang, Xinming and Hong, Xiangxiang and Wang, Xu and Yue, Hui and Wang, Duo and Zhang, Xuemei},
  title = {Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease},
  journal = {BioMed Research International},
  year = {2026},
  doi = {10.1155/bmri/8975137}
}
Kostenlos starten →